



TMH:dv 9/24/05 4239-66645-01 E-090-1996/0-US-06

PATENT
Attorney Reference Number 4239-66645-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Combadiere et al.

Application No. 10/700,313

Filed: October 31, 2003

Confirmation No. 5461

For: CC CHEMOKINE RECEPTOR 5 DNA,
NEW ANIMAL MODELS AND
THERAPEUTIC AGENTS FOR HIV
INFECTION

Examiner: John D. Ulm

Art Unit: 1616

Attorney Reference No. 4239-66645-01

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed September 26, 2005

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
☒ Form 1449 and seven references cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed. Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By _____
Tanya M. Harding, Ph.D.
Registration No. 42,630

cc: Docketing



TM 09/24/05 4239-66645-01 E-090-1996/0-US-06

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Combadiere *et al.*

Application No. 10/700,313

Filed: October 31, 2003

Confirmation No. 5461

For: CC CHEMOKINE RECEPTOR 5 DNA, NEW
ANIMAL MODELS AND THERAPEUTIC
AGENTS FOR HIV INFECTION

Examiner: John D. Ulm

Art Unit: 1616

Attorney Reference No. 4239-66645-01

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed September 26, 2005


INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)


Listed on the accompanying form PTO-1449 and enclosed herewith are seven English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

This IDS is being filed before receipt of a first Office action on the merits. As a result, no fee should be required to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter. The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,
KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By 
Tanya M. Harding, Ph.D.
Registration No. 42,630



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-66645-01
Application Number	10/700,313
Filing Date	October 31, 2003
First Named Inventor	Combadiere
Art Unit	1616
Examiner Name	John D. Ulm

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Choe <i>et al.</i> , "The β -Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates," <i>Cell</i> 85:1135-1148 (June 28, 1996)
		Doranz <i>et al.</i> , "A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β -Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors," <i>Cell</i> 85:1149-1158 (June 28, 1996)
		Dragic <i>et al.</i> , "HIV-1 entry into CD4 ⁺ cells is mediated by the chemokine receptor CC-CKR-5," <i>Nature</i> 381:667-673 (June 20, 1996)
		Kern and Dietrich, "Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution," <i>Blut</i> 52(4):249-254 (April 1986) <i>Abstract Only</i>
		Kuhmann <i>et al.</i> , "Frequent Substitution Polymorphisms in African Green Monkey CCR5 Cluster at Critical Sites for Infections by Simian Immunodeficiency Virus SIVagm, Implying Ancient Virus-Host Coevolution," <i>J Virology</i> 75(18):8449-8460 (September 2001)
		Mackewicz <i>et al.</i> , "Role of β -Chemokines in Suppressing HIV Replication," <i>Science</i> 274:1393-1395 (November 22, 1996)
		Magnani <i>et al.</i> , "The bone marrow in murine AIDS," <i>Br J Haematol.</i> 84(3):539-841 (July 1993) <i>Abstract Only</i>

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.